These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 23340795)
21. [Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole]. Hao J; Yuan BB; Xu YF; Yu J; Liu GY; Wang DH Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):419-24. PubMed ID: 22967442 [TBL] [Abstract][Full Text] [Related]
22. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253 [TBL] [Abstract][Full Text] [Related]
23. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907 [TBL] [Abstract][Full Text] [Related]
24. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells. Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932 [TBL] [Abstract][Full Text] [Related]
25. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Liang K; Lu Y; Li X; Zeng X; Glazer RI; Mills GB; Fan Z Mol Pharmacol; 2006 Sep; 70(3):1045-52. PubMed ID: 16782806 [TBL] [Abstract][Full Text] [Related]
26. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Girgert R; Emons G; Gründker C Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080 [TBL] [Abstract][Full Text] [Related]
27. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression. Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179 [TBL] [Abstract][Full Text] [Related]
28. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Liu P; Kumar IS; Brown S; Kannappan V; Tawari PE; Tang JZ; Jiang W; Armesilla AL; Darling JL; Wang W Br J Cancer; 2013 Oct; 109(7):1876-85. PubMed ID: 24008666 [TBL] [Abstract][Full Text] [Related]
29. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664 [TBL] [Abstract][Full Text] [Related]
30. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. McCrury M; Swafford K; Shuttleworth SL; Mehdi SH; Acharya B; Saha D; Naceanceno K; Byrum SD; Storey AJ; Xu YZ; Doshier C; Patel V; Post GR; De Loose A; Rodriguez A; Shultz LD; Zhan F; Yoon D; Frett B; Kendrick S Mol Cancer Ther; 2024 Mar; 23(3):316-329. PubMed ID: 37816504 [TBL] [Abstract][Full Text] [Related]
31. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939 [TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. Zhao W; Song Y; Xu B; Zhan Q Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935 [TBL] [Abstract][Full Text] [Related]
34. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells. Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563 [TBL] [Abstract][Full Text] [Related]
35. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related]
36. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646 [TBL] [Abstract][Full Text] [Related]
37. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Jang JY; Kim MK; Jeon YK; Joung YK; Park KD; Kim CW Exp Mol Med; 2012 Apr; 44(4):251-9. PubMed ID: 22198296 [TBL] [Abstract][Full Text] [Related]
38. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Tiwary R; Yu W; Sanders BG; Kline K Breast Cancer Res; 2011 Jan; 13(1):R1. PubMed ID: 21214929 [TBL] [Abstract][Full Text] [Related]
39. Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Takahashi K; Tanaka M; Inagaki A; Wanibuchi H; Izumi Y; Miura K; Nagayama K; Shiota M; Iwao H Int J Oncol; 2013 Dec; 43(6):1985-91. PubMed ID: 24126575 [TBL] [Abstract][Full Text] [Related]
40. siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells. Bagheri F; Safarian S; Eslaminejad MB; Sheibani N Cell Oncol (Dordr); 2013 Dec; 36(6):515-26. PubMed ID: 24277473 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]